Added to YB: 2026-08-14
Pitch date: 2026-08-12
AMLX [neutral]
Amylyx Pharmaceuticals, Inc.
-3.81%
current return
Author Info
No bio for this author
Company Info
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Market Cap
$2.6B
Pitch Price
$23.37
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.77
P/E
-16.32
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
BIOTECH MARKET RESEARCH $AMLX | Ep. 1053
AMLX (overview): Catalyst-driven binary on Phase 3 LUCIDITY topline (late-Aug/early-Sep 2026) for avexitide in post-bariatric hypoglycemia. Bull: 5 prior PBH studies, 64% event reduction at 90mg. Bear: best data from tiny 16-pt open-label study vs baseline, never placebo-tested. 2027 launch prep.
Read full article (3 min)